Clinical Phenotypes Associated with NRXN1 Deletions in Five Children with Autism Spectrum Disorder in Oman Authors: Samira Said AlHousni, Ahmed Idris, Watfa Al-Mamari, Abeer Al-Sayegh Published: 2026 ABSTRACT SummaryNRXN1 (2p16.3) is essential for synaptic function and has been implicated in autism spectrum disorder (ASD) and other neurodevelopmental disorders. However, the phenotypic features associated with NRXN1 copy number variants remains incompletely characterised, which complicates risk assessment in genetic counselling. This case series describes five children, who were evaluated at the Genetics and Developmental Pediatrics Clinic of a tertiary care hospital in Muscat, Oman, from 2011 to 2023, with rare NRXN1 deletions (57–150 kb). All met DSM-5 criteria for ASD and had speech and language delays with cognitive impairment. Consanguinity was reported in three of the families and two had a family history of ASD. Microcephaly was present in four children and one showed facial dysmorphism. Generalised tonic-clonic seizures were present in one child and one child had comorbid attention deficit hyperactivity disorder. These findings illustrate clinical heterogeneity among children with NRXN1 deletions and supports the need for larger studies to better define genotype-phenotype relationships. 1. Introduction Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by difficulties in social communication alongside restricted interests and repetitive behaviours.[1] Global estimates suggest that ASD affects approximately 1% of the population and is more frequently diagnosed in males than females (median male-to-female ratio of 4.2); intellectual disability is reported in approximately one-third of cases.[2] Reported prevalence varies widely by region; for example, a review of Middle Eastern studies reported an estimate of 0.63 per 10,000 children, whereas recent surveillance data from the United States suggest a prevalence of approximately 1 in 59 children.[34] Differences in awareness, service access, diagnostic pathways, help-seeking behaviour and sociodemographic factors are likely to contribute to this variability.[25] ASD is strongly heritable and genetically heterogeneous. Concordance rates are substantially higher in monozygotic than dizygotic twins (approximately 70–90% versus up to 10%), supporting a major genetic contribution.[6] Consistent with this, sibling recurrence risk is increased, particularly among males.[7] A genetic aetiology can be identified in approximately 20–34% of individuals with ASD, including de novo variants and rare and common inherited variants, as well as ASD-associated polymorphisms.[8] Among implicated loci, NRXN1 (neurexin 1) on chromosome 2p16.3 plays a central role in synaptic function and has been associated with ASD and other neurodevelopmental disorders.[9] NRXN1 spans approximately 1.12 Mb and is regulated by two independent promoters, generating two main isoforms: the longer NRXN1α and the shorter NRXN1β.[10] NRXN1 is structurally diverse, largely because its transcripts undergo extensive alternative splicing. The NRXN1α isoform contains six canonical splice sites, two of which (sites 4 and 5) are shared with NRXN1β.[11] Evidence from RNA sequencing of human post-mortem brain tissue suggests that NRXN1 is expressed in the cortex early in gestation, before synaptogenesis becomes established, with detectable transcripts between gestational weeks 8 and 12.[1011] This developmental profile is consistent with a role for NRXN1 in early cortical maturation and synapse formation. NRXN1 genetic variation, particularly deletions, has been linked to a range of neurodevelopmental and neuropsychiatric outcomes, including intellectual disability, global developmental delay, speech and language impairment, epilepsy and schizophrenia.[1213] Deletions affecting NRXN1 exons, especially those near the 5’ end, have been linked to increased risk of ASD and schizophrenia.[14] Heterozygous NRXN1 variants have also been associated with ASD, further implicating NRXN1 in social-communication difficulties characteristic of the disorder.[15] In light of this, this case series describes the clinical features of five children diagnosed with ASD who were found, through genetic testing, to carry NRXN1 deletions. This report aimed to characterise the phenotypic spectrum associated with NRXN1 deletions and to contribute Oman-specific evidence to the literature, given the limited regional data. The findings are intended to inform interpretation of clinical variability and recurrence risk assessment in genetic counselling. 2. Methods This case series evaluated children who presented to the Genetics and Developmental Paediatric Clinic at a tertiary care hospital in Muscat, Oman, between 2011 and 2023. Electronic records were reviewed retrospectively; children were included if they had a diagnosis of ASD, were aged 14 years or younger, had undergone a comprehensive phenotypic assessment by developmental paediatrics and medical genetics specialists and had an NRXN1 finding reviewed and interpreted by a clinical geneticist. Extracted clinical information included physical features, ASD-related neurodevelopmental profile, and comorbidities. In this cohort, not all children with ASD underwent array CGH due to deliberate, clinically guided selection rather than universal testing. Array CGH was performed in children with ASD who fulfilled the institutional clinical criteria for genomic testing, following informed parental consent. The criteria guiding genetic testing in this cohort have been consistently applied and previously detailed in previous publications.[81617] ASD was diagnosed according to DSM-5 criteria using standardised procedures by a multidisciplinary team led by a developmental paediatrician. Medical geneticists reviewed clinical features and genetic findings to support genetic counselling, assess recurrence risk and evaluate variant pathogenicity. Peripheral blood samples were obtained from patients and parents during clinical evaluation and sent to accredited diagnostic laboratories for analysis such as Sistemas Genómicos (Valencia, Spain), CENTOGENE AG (Rostock, Germany) or Fulgent Genetics (Temple City, California, USA). Genomic DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen, Courtaboeuf, France). Chromosomal microarray analysis was performed using a 4×180 CGH+SNP microarray platform (SurePrint G3 Human, Agilent Technologies, Santa Clara, USA). Data were analysed using Agilent CytoGenomics software, Version 4.0.3.12, with the Aberration Detection Method 2 algorithm (ADM-2, threshold 6.0) to detect copy number changes. Variant interpretation followed American College of Medical Genetics and Genomics guidance.[1819] Children with NRXN1 variants were then identified for inclusion. Clinical reports were blindly reviewed by an independent local clinical geneticist for classification of sequence variants against a local database, following the availability of further segregation analysis. 3. Results A total of 1,760 children attended the clinic; 710 children aged 1.5–14 years underwent chromosomal microarray analysis, from which five children with NRXN1 deletions associated with ASD were identified. The cohort comprised five children (aged 2–13 years) from different regions of Oman who were diagnosed with ASD and carried NRXN1 deletions. Consanguinity was reported in three families. Physical examination demonstrated variability in dysmorphic features, with patient 3 showing brachycephaly, a flat facial profile and a long philtrum. One child was assessed for visual concerns and was found to have compound astigmatism in both eyes. Microcephaly was present in four of the five children [Table 1]. Table 1.Demographic and physical characteristics of five patients with NRXN1 copy number variants.PatientAge atWeight inHeight inDysmorphic#Sexdiagnosis in yearsConsanguinitypercentilepercentileHC SDVisionHearingfeatures1M7Yes1050–2.1Bilateral compound astigmatismNormalNone2F5Yes5010–4.5NormalNormalNone3M13No50900.0NormalNormalBrachycephaly, flat facial profile, long philtrum4M2Yes1010–2.6NormalNormalNone5M7No310–2.1NormalNormalNoneHC SD = head circumference standard deviation; M = male; F = female. Demographic and physical characteristics of five patients with NRXN1 copy number variants. HC SD = head circumference standard deviation; M = male; F = female. ASD was confirmed in all children using the Autism Diagnostic Interview-Revised (ADI-R) and Autism Diagnostic Observation Schedule, Second Edition, administered by a developmental paediatrician. All children had moderate intellectual disability and speech delay. Generalised tonic-clonic seizures were reported in one child; none of the children showed neurodevelopmental regression. Two children had comorbid attention-deficit/hyperactivity disorder (ADHD) and a family history of ASD was reported in two cases. Chromosomal microarray analysis identified NRXN1 deletions (2p16.3) in all five children, with deletion sizes ranging from 57 kb to 150 kb [Table 2 and Fig. 1]. No duplications were detected. Deletion regions in five patients highlighting NRXN1 on chromosome 2p16.3. Table 2.Neurodevelopmental phenotype of five patients with NRXN1 copy number variants.PatientMotorLanguage delay (expressive,CognitiveBrain MRI#delayHypotoniareceptive or both)ADHDimpairmentSeizure/typefindings1NoNoBothNoModerateGeneralised tonic-clonicFeatures suggestive of left mesial temporal sclerosis2NoNoBothYesModerateNo seizuresNot done3NoNoBothNoModerateNo seizuresNo intracranial abnormality4NoNoBothNoModerateNo seizuresNo intracranial abnormality5NoNoBothYesModerateNo seizuresNo intracranial abnormalityADHD = attention-deficit hyperactivity disorder; MRI = magnetic resonance imaging. Neurodevelopmental phenotype of five patients with NRXN1 copy number variants. ADHD = attention-deficit hyperactivity disorder; MRI = magnetic resonance imaging. Case 3 involved multiple mutations in addition to the NRXN1 deletion and included two additional mutations. The first is an interstitial deletion of the 7q32.1–q32.3 region, with a minimum size of 3.0 Mb; no comparable deletions in this region have been reported in the literature. The second mutation is a duplication at Xp22.11, with a minimum size of 280 kb. The clinical significance of this duplication in a male carrier remains unknown. Karyotyping was not performed at that time to rule out a chromosomal rearrangement. Furthermore, case 5 had additional variants, although no distinct clinical features were apparent that could be attributed to these findings [Table 3]. Whole-exome sequencing was not performed, limiting further genetic exploration. Table 3.Summary of the molecular features of five patients with NRXN1 copy number variants.PatientChromosomalDeletionGenesCNVCNVWESInherited or#locationsizeinvolveddeletionduplicationdonede novo1arr[hg19] 2p16.3(50,250,430-50,310,026)x160 kb NRXN1 YesNoNoPaternally inherited2arr[hg19] 2p16.3(50,882,091-50,992,285)x1 mat110 kb NRXN1 YesNoNoMaternally inherited3arr[hg19] Xp22.11(22,156,804-22,438,749)x2, 2p16.3(51,067,055-51,218,716)x1, 7q32.1q32.3(128,972,820-131,984,276)x1150 kb NRXN1 YesNoNoUnknown4arr[GRCh37] 2p16.3(50829059_50954600)x1126 kb NRXN1 YesNoNoDe novo5arr[GRCh37] 2p16.3(51107486 1164931)x157 kbNRXN1 KCNIP4 LOC100505912 ADGRA3 GBA3 CDH9YesNoNoUnknownCNV = copy number variant; WES = whole-exome sequencing. Summary of the molecular features of five patients with NRXN1 copy number variants. CNV = copy number variant; WES = whole-exome sequencing. Parental and siblings testing for the NRXN1 deletion demonstrated variable inheritance patterns across the case series. In Case 1, the father was an asymptomatic carrier for the NRXN1 deletion while the mother tested negative. In Case 2, the same variant was detected in both the mother and the patient's brother; the brother exhibited a comparable phenotype consistent with ASD, whereas the mother was clinically unaffected and reported no history of developmental delay or neuropsychiatric conditions. In Case 4, both parents tested negative for the deletion, supporting a de novo event in the proband. In Cases 3 and 5, parental testing was not performed due to refusal. 4. Discussion This case series describes the clinical manifestations associated with NRXN1 deletions in five children diagnosed with ASD, from different regions in Oman. Marked variability was observed across neurodevelopmental and physical features, which is consistent with the recognised phenotypic breadth reported in association with NRXN1-related neurodevelopmental conditions. All children in this series met criteria for ASD and had cognitive impairment with speech and language delay. The proportion of ASD, intellectual disability and seizure phenotypes in this cohort appears higher than that reported by Ching et al., who described individuals with whole-gene or multi-exon deletions and intronic deletions, among whom 33% had ASD, 17% had intellectual disability and 8% had seizures, while language delay was reported in 75%.[12] Speech and language delay has also been highlighted as a frequent feature in individuals with confirmed NRXN1-associated phenotypes.[20] The higher frequency of neurodevelopmental impairment in the current series may reflect case ascertainment within a specialist clinic cohort enriched for ASD, as well as differences in deletion size, breakpoint location and clinical evaluation pathways across studies. Behavioural and psychiatric comorbidity was observed in this cohort, including one child with comorbid ADHD, additional hyperactive behaviours and emotional dysregulation in two children. These findings are broadly aligned with earlier reports linking NRXN1 variants with co-occurring psychiatric presentations, including ADHD, anxiety, depression and schizophrenia.[2122] One child had generalised tonic-clonic seizures. Seizure phenotypes have also been reported among individuals with NRXN1 deletions, including absence seizures with electroencephalographic findings consistent with generalised epilepsy.[12] Together, these observations support maintaining clinical vigilance for epileptic activity in children with ASD who carry NRXN1 deletions, particularly when suggestive symptoms emerge. Dysmorphic features were variable and, where present, tended to be minor. Patient 3 had brachycephaly, a flat facial profile and a long philtrum; however, no consistent pattern of major dysmorphology was evident across the cohort. Microcephaly was common in this series and may represent a relevant associated feature, although the evidence base remains limited and larger studies are required to clarify its prevalence and clinical significance among NRXN1 deletion carriers. In a recent review of 71 individuals with NRXN1 variants and ASD, facial dysmorphic features were reported in four cases, and macrocephaly or relative macrocephaly was reported in two cases.[11] In the current cohort, microcephaly or relative microcephaly was observed frequently. In addition, one child had more marked microcephaly, with head circumference substantially below the mean. These findings may indicate that reduced head circumference warrants particular attention during clinical assessment, although genotype-phenotype inference remains preliminary in a small series. Almost all the cases presented with moderate cognitive impairment along with delays in both expressive and receptive language, independent of NRXN1 variant size. However, additional phenotypic features were observed in Cases 1, 2 and 5. Case 1 had generalised tonic-clonic seizures, whereas Cases 2 and 5 had comorbid ADHD. In contrast, Case 3, despite carrying the largest variant, did not present with seizures or ADHD. Although the location of NRXN1 deletions, particularly within the alpha isoform, strongly influences phenotypic outcomes, the size of the deletion is not consistently associated with the severity of the disease. [23] The current evidence on NRXN1 genotype–phenotype relationships indicate a highly complex and heterogeneous pattern. Rare deletions in this gene are associated with a markedly elevated risk of a wide range of neurodevelopmental disorders, accompanied by considerable variability in clinical presentation. Cooper et al. emphasised the pronounced diversity in both genetic and phenotypic features of ASD among individuals carrying NRXN1 mutations, underscoring the importance of continued research to better understand the intricate genetic mechanisms involved.[24] The results of parental and sibling analyses indicate that NRXN1 deletions within this cohort occur via both inherited and de novo events, with observed reduced penetrance and variable phenotypic expression among carriers. These findings underscore the value of thorough family genetic evaluation to accurately define inheritance patterns and inform genetic counselling. Chromosomal microarray analysis enabled detection of NRXN1 deletions in all cases, however, the absence of whole exome sequencing limited further evaluation of additional rare variants that might contribute to individual clinical profiles. Broader genomic testing may help refine interpretation in future work, particularly for children with additional variants identified on microarray. A key limitation of this case series is the absence of an age- and sex-matched control group of Omani children without ASD, which limits accurate estimation of the incidence and phenotypic spectrum of NRXN1 copy number variants (CNVs). Genetic testing in our setting is primarily performed in children with suspected neurodevelopmental disorders; therefore, data on NRXN1 CNVs in the general paediatric population are lacking. Future studies including appropriate control cohorts are needed to improve the interpretability and generalisability of these findings. 5. Conclusion This case series highlights the variable phenotypic spectrum associated with NRXN1 deletions among children with ASD in Oman. The clinical features observed, including speech and language delay, cognitive impairment, generalised tonic-clonic seizures, microcephaly and behavioural comorbidity, support the value of early genetic evaluation to refine diagnosis and inform individualised clinical management. Further studies with larger cohorts are needed to characterise genotype-phenotype relationships and to clarify the contribution of NRXN1 deletions to neurodevelopmental outcomes and associated physical features; the inclusion of such a control population would provide valuable context for interpreting the incidence and phenotypic spectrum of NRXN1 CNVs. Furthermore, deletion size in NRXN1 was not consistently associated with clinical severity. Both inherited and de novo deletions were observed, with evidence of reduced penetrance and variable phenotypic expression among carriers. These findings highlight the importance of comprehensive family genetic evaluation to clarify inheritance patterns and support informed genetic counselling. Authors’ Contribution Samira Said AlHousni: Conceptualization, Investigation, Data Curation, Visualization, Writing – Original Draft, Writing – Review & Editing, Project Administration. Ahmed Idris: Conceptualization, Methodology, Resources, Supervision, Writing – Review & Editing. Watfa Al-Mamari: Supervision, Writing – Review & Editing. Abeer Al-Sayegh: Validation, Writing – Review & Editing. Ethics Statement Ethical approval was obtained from the Medical Research and Ethics Committee at Sultan Qaboos University, Oman (MREC #752). The report adheres to the World Medical Association Declaration of Helsinki with respect to confidentiality, privacy and data management. Conflict of Interest The authors declare no conflicts of interest. Funding No funding was received for this study. Data Availability Data are available upon reasonable request from the corresponding author.